Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMIGKA1)

Drug Name

Ozagrel Drug Info

Synonyms

Ozagrel (ophthalmic, eye disorders); Ozagrel (ophthalmic, eye disorders), Kissei/ Teika

Indication

Disease Entry	ICD 11	Status	REF
Xerophthalmia	5B55.Y	Phase 4	[1]
Chronic obstructive pulmonary disease	CA22	Phase 1	[2]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Stress-activated protein kinase 2a (p38 alpha)	TTQBR95	MK14_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Stress-activated protein kinase 2a (p38 alpha)	DTT	MAPK14	7.103	6.87	6.74	6.306

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Xerophthalmia

ICD Disease Classification

5B55.Y

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Stress-activated protein kinase 2a (p38 alpha)	DTT	MAPK14	4.95E-14	0.48	1.09

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT00200356) Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke. U.S. National Institutes of Health.
2	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028430)
3	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).